Catheter-delivered, self-contained pacing capsule implanted directly into the right ventricle via femoral vein — no leads, no pocket
Leadless pacemaker implantation begins not at the heart but at the groin. Using the modified Seldinger technique, a large-bore (typically 23-27 Fr outer diameter for the steerable delivery catheter) venous access sheath is placed in the femoral vein — the same entry point used for many structural heart and electrophysiology procedures. From here, the entire pacing system is delivered percutaneously to the right ventricle without ever creating a subcutaneous pocket or threading a lead through the venous system.
Conventional transvenous pacemakers require two separate anatomic insults: a subclavian or cephalic venous puncture for the lead, and a subcutaneous pectoral pocket for the pulse generator. Both are sources of long-term complication. Leadless systems eliminate both by using a single femoral venous access point and delivering a fully self-contained, lead-free capsule directly to its final resting place inside the heart.
The femoral vein is chosen because it accommodates the large-bore steerable delivery catheter (comparable in caliber to sheaths used for transcatheter aortic valve or MitraClip delivery) far more comfortably than upper-extremity veins, and because the resulting trajectory — inferior vena cava (IVC) to right atrium to right ventricle — provides a naturally favorable curve for steering the catheter tip toward the interventricular septum.
Access is obtained under fluoroscopic and/or ultrasound guidance using a micropuncture technique to minimize vascular injury, followed by serial dilation to accommodate the delivery sheath. Because the device is retrievable and the sheath is large, meticulous hemostasis technique (including figure-of-eight sutures or vascular closure devices) is used at the end of the case.
Eliminating the pocket removes the single most common site of complication in conventional pacing: pocket hematoma, erosion, and pocket infection account for roughly 60% of all transvenous pacemaker-related adverse events.
After the sheath is placed, the catheter is advanced under fluoroscopic guidance cephalad through the external and common iliac veins into the inferior vena cava, then into the right atrium. Contrast venography or intracardiac echocardiography (ICE) is frequently used to confirm luminal position and avoid dissection, particularly in patients with tortuous iliofemoral anatomy, prior filters, or venous stenosis from previous instrumentation.
The delivery catheter itself is a coaxial system: an outer steerable sheath provides gross deflection and support, while an inner catheter houses the capsule in a docked, low-profile configuration with its tines constrained against the shaft. Radiopaque markers on both the sheath tip and the capsule allow precise fluoroscopic tracking throughout the delivery sequence, typically visualized in a shallow right anterior oblique (RAO) or left anterior oblique (LAO) projection to profile the septum.
Cardiac implantable electronic device (CIED) infection remains one of the most feared complications in cardiac rhythm management, with reported rates of 1-2% for de novo implants and considerably higher for reoperations, carrying mortality as high as 18-34% when systemic (lead-associated endocarditis) infection occurs.
Because the leadless capsule has no subcutaneous pocket, no header, and no transvenous lead body — the three anatomic substrates on which CIED infections classically develop (pocket erosion, generator-pocket biofilm, and lead-associated vegetations) — large registries (LEADLESS II, Micra IDE/CED studies) have shown major infection rates below 0.3%, roughly an order of magnitude lower than historical transvenous cohorts. This makes leadless pacing particularly attractive in dialysis patients, those with prior device infection, and immunocompromised hosts.
With the catheter tip in the right atrium, the operator must now steer a relatively rigid, large-bore delivery system across the tricuspid valve and into the right ventricle without damaging the valve apparatus, then torque and deflect the tip to reach a stable, septal (rather than free-wall or apical) target — all while the heart continues to beat around the instrument.
The tricuspid valve is crossed using a controlled combination of catheter deflection, gentle advancement, and clockwise/counterclockwise torque, guided continuously by fluoroscopy and often intracardiac echocardiography. The catheter's primary curve is pre-shaped to approximate the natural angle between the IVC/RA junction and the tricuspid annulus, minimizing the force needed to cross.
Operators avoid excessive forward force while the tip is engaging valve leaflets or chordae, since the delivery catheter — unlike a soft guidewire — is stiff enough to injure tricuspid leaflets, cause chordal entanglement, or induce transient heart block from mechanical trauma to the conduction system as it passes near the His bundle region. Deflection is instead built up progressively: partial deflection to align the tip with the valve orifice, gentle advancement through diastole, then straightening slightly once the tip is ventricular.
Once inside the right ventricle, the catheter tip is actively deflected and rotated to point at the mid-to-low interventricular septum — the preferred implant target for nearly all leadless systems. The septum is favored over the RV apex or free wall for several reasons:
• Septal myocardium is thicker and more fibrous, providing more robust purchase for the fixation tines • A septal position is associated with a more physiologic (narrower, more synchronous) paced QRS morphology than apical pacing • The free wall carries a materially higher risk of perforation given its thinner, more compliant myocardium
Correct septal positioning is confirmed fluoroscopically: in the RAO projection, the capsule should point toward the spine (septal orientation), while in the LAO projection the tip should not swing freely with cardiac motion (a sign of free-wall or outflow tract positioning, which paces poorly and risks perforation).
Operators use the "spin test" during navigation — rotating the catheter tip while observing fluoroscopic motion — to distinguish true septal contact (tip stays fixed as the catheter rotates) from free-wall or apical placement (tip swings with respiration and cardiac motion).
Most operators combine fluoroscopy with at least one adjunct imaging modality to improve septal localization and reduce perforation risk:
• Intracardiac echocardiography (ICE): direct visualization of the tip against septal myocardium, tenting of the endocardium during force application, and immediate detection of pericardial effusion • Electrograms from the capsule itself: a unipolar injury current pattern and local electrogram amplitude help confirm true myocardial (versus intracavitary) contact before any tine deployment is attempted • Contrast injection: a small hand injection through the delivery catheter can outline the RV cavity and confirm the tip is not engaging a trabeculation or the moderator band
This is the decisive moment of the implant: the capsule is advanced beyond the catheter tip, pressed firmly against the septal endocardium, and its self-expanding nitinol tines are actively deployed to penetrate and anchor into the myocardium. Unlike a passive-fixation lead that simply wedges into trabeculae, the leadless capsule achieves genuine active fixation — a mechanical bond confirmed in real time before the delivery catheter is ever detached.
With the capsule tip held firmly against the septum under gentle continuous forward pressure, the operator releases a locking mechanism that allows the four nitinol tines — previously constrained in a straightened configuration inside the delivery catheter — to spring outward into their pre-set curved shape. Nitinol's shape-memory and superelastic properties are essential here: the alloy can be elastically deformed to a low-profile straight configuration for catheter delivery, then reliably return to its manufactured curved geometry once unconstrained, generating consistent outward and rotational force against the tissue.
As the tines expand, continued gentle forward pressure from the delivery catheter drives their sharpened tips into the septal endocardium and subendocardial myocardium, typically to a depth of one to two millimeters — enough to anchor firmly without risking transmural perforation in a septum that is normally 8-10 mm thick.
Before the capsule is mechanically detached from its delivery catheter, the operator performs a "tug test": gentle, controlled retraction of the catheter while it remains attached to the capsule, applying tension roughly 1.5 times greater than the force the device is expected to experience chronically from cardiac contraction and blood flow.
A successfully fixed capsule will resist this tug, moving minimally or showing only slight recoil before returning to position, with no change in electrogram signal or fluoroscopic position. If the capsule dislodges or shows inadequate resistance, it is fully retracted back into the catheter (a maneuver unique to active-fixation leadless systems and impossible with a chronically implanted transvenous lead) and redeployed at a new site — with no tissue trauma penalty for the attempt, since the tines that failed to gain purchase are simply re-sheathed.
Only after a satisfactory tug test, confirmed by fluoroscopic stability and stable electrical parameters, is the capsule permanently released from the delivery catheter via a separate mechanical detachment mechanism.
Because the capsule can be recaptured and redeployed multiple times before final release, operators can attempt several implant sites without any cumulative myocardial injury — a fundamental advantage over lead-based active-fixation systems, where each screw-in attempt leaves permanent tissue trauma.
The earliest and still most widely used leadless pacemakers are single-chamber VVI(R) devices, pacing and sensing only the right ventricle — appropriate for patients with permanent atrial fibrillation and AV block, or infrequent ventricular pacing needs. Newer-generation dual-chamber leadless systems add a second, smaller capsule implanted in the right atrial appendage that communicates wirelessly (via beat-to-beat implant-to-implant conduction through the cardiac tissue and bloodstream) with the ventricular capsule, restoring atrioventricular synchrony without any lead crossing the tricuspid valve.
This dual-capsule architecture required solving a substantial engineering challenge: achieving reliable, low-latency, low-power communication between two independent implants using intrabody conducted communication rather than radiofrequency telemetry, which would rapidly deplete each device's battery.
With the capsule mechanically anchored, its two integrated electrodes — mounted directly on the device housing rather than at the end of a meters-long lead — are used to measure pacing threshold, sensing amplitude, and electrode impedance in real time. Because there is no lead body, no connector, and no header contact to introduce resistance or failure points, these measurements reflect the device-to-tissue interface with unusual fidelity.
In a conventional transvenous system, the electrical signal must pass through a lead conductor coil or cable (often 50-60 cm long), a connector pin, and a header block before reaching the pulse generator circuitry — each an opportunity for insulation breach, conductor fracture, or connection failure over years of implant life. The leadless capsule collapses this entire chain: its two electrodes (a distal tip electrode integrated with the fixation tines, and a proximal ring electrode on the capsule body) connect directly to the internal circuitry with no intervening hardware.
This architecture is a major driver of the leadless system's favorable long-term reliability profile — lead-related complications (fracture, insulation failure, dislodgement) account for a substantial share of all conventional pacemaker reinterventions, and are structurally impossible in a system with no lead.
Three parameters are measured before the operator commits to final capsule release, and again before hospital discharge:
• Pacing threshold: the minimum electrical energy (voltage at a fixed pulse width, typically 0.4 ms) required to reliably capture the ventricle. Values under 1.0 V indicate excellent tissue contact; thresholds are typically lower and more stable with leadless systems than with historical passive-fixation leads because the tines guarantee direct myocardial contact rather than trabecular wedging.
• R-wave sensing amplitude: the intrinsic electrogram signal amplitude recorded by the device when the ventricle depolarizes on its own. Adequate amplitude (generally >5 mV) ensures the device reliably detects native beats and avoids both under-sensing (missed native beats, resulting in inappropriate pacing) and over-sensing (inappropriate inhibition).
• Electrode impedance: the resistance of the tissue-electrode interface, which should fall in a moderate range — too low suggests an insulation or short-circuit problem, too high suggests poor contact or a fractured conductor pathway (though the latter is not a failure mode leadless devices can experience in the traditional sense).
Because tine engagement quality directly determines electrode-tissue contact area, threshold and sensing values measured immediately after fixation are highly predictive of chronic (long-term) performance — a key reason the tug test and electrical testing are performed together before final capsule release.
Leadless pacemakers are designed and labeled as MR-conditional, allowing full-body magnetic resonance imaging under specified conditions — a meaningful advantage given that a large proportion of pacemaker recipients will need an MRI at some point after implant. The absence of a lead removes the principal MRI hazard in conventional systems: lead-tip heating from radiofrequency energy deposition, which can cause local myocardial injury or threshold changes.
Because the capsule paces from a septal location with direct electrode-myocardium contact, the resulting paced QRS is typically narrower and more synchronous than apical pacing from a conventional right-ventricular lead — an early physiologic advantage, though leadless systems still lack the full His-bundle or left-bundle-branch conduction system pacing achievable with specialized lead-based techniques.
Once fixation and electrical parameters are confirmed satisfactory, the capsule is permanently released and the now-empty delivery catheter is withdrawn from the body, leaving nothing behind except the self-contained device anchored in the right ventricle. From this point forward, the capsule operates entirely independently for a projected 10-15 years, and — unlike a lead, which is essentially never removed once endothelialized — remains retrievable by snare if revision is ever needed.
After the electrical parameters are confirmed acceptable and the tug test passed, the operator activates the mechanical release mechanism that permanently separates the capsule from the delivery catheter. The inner catheter is then withdrawn back into the outer steerable sheath, and the entire delivery system is removed from the venous system under fluoroscopic observation to confirm the capsule remains stably fixed and no pericardial effusion has developed.
Hemostasis is achieved at the femoral venous access site, and patients are typically observed with echocardiography to exclude pericardial effusion before discharge — most protocols call for same-day or next-day discharge given the minimally invasive nature of the procedure compared with conventional pocket-based implantation.
Leadless capsule battery life is determined by the same fundamentals as any implanted pacemaker: energy consumption is dominated by the pacing threshold, the percentage of time the device paces versus senses intrinsic rhythm, pulse width, and heart rate — but is achieved in a dramatically smaller volume (roughly 1 cc, versus 10-15 cc for a conventional pulse generator).
Modern leadless devices achieve projected longevity in the same range as, or exceeding, many conventional single-chamber pacemakers (roughly 10-15 years depending on programmed settings and percent pacing), owing to low chronic thresholds from stable active fixation, power-efficient circuitry, and advanced battery chemistry packed into the capsule housing. Devices continuously estimate remaining longevity and provide programmer alerts as elective replacement indicators approach, allowing planned intervention well before battery depletion.
Because the entire device — battery, circuitry, and electrodes — is replaced as a single unit at end of battery life (typically by deploying a second capsule and leaving the depleted one in place, rather than extracting it), leadless systems avoid the surgical revision required to swap a conventional pulse generator, though multiple deployed capsules must be accounted for in future device selection.
A frequently underappreciated feature of leadless pacemakers is that they remain retrievable even after chronic implantation, unlike conventional leads whose fibrous encapsulation makes extraction increasingly risky over time. The capsule incorporates a dedicated retrieval feature — typically a small docking button or loop at its proximal end — engineered specifically to be captured by a gooseneck snare advanced through a femoral venous sheath.
Published case series have demonstrated successful percutaneous retrieval of leadless capsules years after implantation, for indications including infection, elective device upgrade, or battery depletion in select cases. Retrieval becomes technically more demanding as fibrous tissue overgrowth increases with time, and beyond a certain point (often several years) an old, depleted capsule may instead simply be abandoned in place — electrically inert but mechanically inconsequential — while a new capsule is implanted alongside it, since RV volume comfortably accommodates more than one device.